NYSEARCA:XBI SPDR S&P Biotech ETF (XBI) Price, Holdings, & News $89.92 +0.70 (+0.78%) Closing price 08/21/2025 04:10 PM EasternExtended Trading$90.26 +0.34 (+0.38%) As of 06:40 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisChartDividendHeadlinesHoldingsOwnershipRatingsShort InterestBuy This Stock About SPDR S&P Biotech ETF (NYSEARCA:XBI) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get SPDR S&P Biotech ETF alerts:Sign Up Key Stats Today's Range$88.23▼$90.0350-Day Range$82.10▼$90.6852-Week Range$66.66▼$105.47Volume8.43 million shsAverage Volume10.59 million shsMarket Capitalization$4.90 billionAssets Under Management$5.12 billionDividend Yield0.03%Net Expense Ratio0.35%Aggregate RatingModerate Buy ETF Overview SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges. The Biotech Index is a modified equal weight index. SSgA Funds Management, Inc. is the Fund's investment advisor. Read More SPDR S&P Biotech ETF ExpensesTypeXBIHealth Care ETFsEquity ETFsNYSEARCA ETFsAll ETFsManagement Fee0.35%0.56%0.56%0.51%0.53%Other Expenses0.00%0.47%0.56%0.59%0.56%Total Expense0.35%0.75%0.76%0.74%0.73%Fee Waiver0.00%-0.67%-0.66%-0.71%-0.63%Net Expense0.35%0.60%0.63%0.58%0.60% Receive XBI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for SPDR S&P Biotech ETF and its competitors with MarketBeat's FREE daily newsletter. Email Address XBI ETF News HeadlinesInside XBI: What The SPDR S&P Biotech ETF Offers InvestorsAugust 19 at 12:31 PM | seekingalpha.comXBI: Surprise Exit Of A Tough Regulator At The FDAJuly 30, 2025 | seekingalpha.comTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now. | Porter & Company (Ad)Biotech stocks dip as Trump administration mulls patent fee overhaulJuly 28, 2025 | finance.yahoo.comSPDR S&P Biotech ETF (XBI) - Yahoo FinanceJuly 8, 2025 | finance.yahoo.comXBI Chart | SPDR S&P Biotech ETF - Investing.comJune 25, 2025 | investing.comSee More Headlines XBI ETF - Frequently Asked Questions How have XBI shares performed this year? SPDR S&P Biotech ETF's stock was trading at $90.06 at the beginning of 2025. Since then, XBI shares have decreased by 0.2% and is now trading at $89.92. Who are SPDR S&P Biotech ETF's major shareholders? Top institutional investors of SPDR S&P Biotech ETF include JPMorgan Chase & Co. (19.54%), Jane Street Group LLC, Rubric Capital Management LP and Capital Fund Management S.A.. How do I buy shares of SPDR S&P Biotech ETF? Shares of XBI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of SPDR S&P Biotech ETF own? Based on aggregate information from My MarketBeat watchlists, some other companies that SPDR S&P Biotech ETF investors own include American Water Works (AWK), Waste Connections (WCN), The RMR Group (RMR), iShares Micro-Cap ETF (IWC), Voyager Therapeutics (VYGR), DiamondRock Hospitality (DRH) and Humana (HUM). Fund Details IssuerSSgA Fund NameSPDR S&P Biotech ETF Tax ClassificationRegulated Investment Company Stock ExchangeNYSEARCACurrent SymbolNYSEARCA:XBI Inception Date1/31/2006 Fund ManagerMichael Feehily, Karl Schneider, Raymond Donofrio Webwww.spdrs.com Phone+1-866-7872257Fund Focus Asset ClassEquity BenchmarkS&P Biotechnology Select Industry Index CategorySector FocusHealth Care Development LevelDeveloped Markets RegionNorth America Number of Holdings135 Fund Statistics Assets Under Management$5.12 billion Average Daily Volume$9.88 million Discount/Premium0.02% Administrator, Advisor and Custodian AdministratorSSgA Funds Management, Inc. AdvisorSSgA Funds Management, Inc. CustodianState Street Bank and Trust Company DistributorState Street Global Advisors Funds Distributors, LLC Transfer AgentState Street Bank and Trust Company TrusteeN/A Lead Market MakerVirtu Financial Options OptionableOptionable Options Volume20,337 Put Options16,422 Call Options3,915 Short Interest79,500,000 shs Miscellaneous Outstanding Shares54,450,000Beta0.97 Creation Unit50,000 Creation Fee$250.00 7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Top 10 XBI HoldingsAlnylam Pharmaceuticals (NASDAQ:ALNY)Holding Weight: 3.61%Halozyme Therapeutics (NASDAQ:HALO)Holding Weight: 3.06%Insmed (NASDAQ:INSM)Holding Weight: 3.06%Incyte (NASDAQ:INCY)Holding Weight: 2.92%United Therapeutics (NASDAQ:UTHR)Holding Weight: 2.67%Regeneron Pharmaceuticals (NASDAQ:REGN)Holding Weight: 2.60%Gilead Sciences (NASDAQ:GILD)Holding Weight: 2.54%AbbVie (NYSE:ABBV)Holding Weight: 2.53%Neurocrine Biosciences (NASDAQ:NBIX)Holding Weight: 2.52%Biogen (NASDAQ:BIIB)Holding Weight: 2.46%Full Holdings DetailsXBI Sector ExposureXBI Industry Exposure This page (NYSEARCA:XBI) was last updated on 8/22/2025 by MarketBeat.com Staff From Our Partners[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredUS attacks China, September 30?The White House just ordered more than 400 government agencies to prepare for the next phase of America’s econ...Stansberry Research | SponsoredOne tiny company just cracked Google’s $19B problemGoogle’s AI-powered search could cost $20 billion a year in electricity—nearly half its profits. But new resea...True Market Insiders | SponsoredBut this $20 American company could control the secretThe "Impossible" Chip That Runs on Pure Light Google's quantum computer shocked the world... but China DEMO...The Oxford Club | SponsoredI trusted Trump and got screwedPorter Stansberry says he got one thing wrong—and now millions of Americans could pay the price. After warning...Porter & Company | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SPDR S&P Biotech ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share SPDR S&P Biotech ETF With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.